The content on this site is intended for healthcare professionals only
Dr Wolchok presents, at a press conference at ASCO 2015, findings from a randomised phase III trial indicate that initial therapy with nivolumab alone or in combination with ipilimumab is significantly more effective than ipilimumab alone.
Read the news article and watch the video interview for more.
Biomarkers, predictive and prognostic factors of resistance to immunotherapy
GIST tumours and soft tissue sarcomas
Hormonal receptor positive breast cancer adjuvant and metastatic indications
ASCO 2024: Lung cancer highlights
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Multiple myeloma in a resource constrained setting
Relapsed refractory multiple myeloma
Adding new vaccine type to leading immunotherapy dramatically reduces melanoma recurrence
Four chemo cycles given with durvalumab and tremelimumab optimise response and tumour shrinkage in patients with mNSCLC
